Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Equity (2021 - 2025)

Historic Return on Equity for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to 2.81%.

  • Rhythm Pharmaceuticals' Return on Equity rose 74300.0% to 2.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.81%, marking a year-over-year increase of 74300.0%. This contributed to the annual value of 2.72% for FY2024, which is 18700.0% down from last year.
  • Rhythm Pharmaceuticals' Return on Equity amounted to 2.81% in Q3 2025, which was up 74300.0% from 52.01% recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Return on Equity's 5-year high stood at 0.06% during Q2 2021, with a 5-year trough of 52.01% in Q2 2025.
  • In the last 5 years, Rhythm Pharmaceuticals' Return on Equity had a median value of 0.91% in 2023 and averaged 5.46%.
  • The largest annual percentage gain for Rhythm Pharmaceuticals' Return on Equity in the last 5 years was 74300bps (2025), contrasted with its biggest fall of -468700bps (2025).
  • Rhythm Pharmaceuticals' Return on Equity (Quarter) stood at 0.26% in 2021, then crashed by -159bps to 0.66% in 2022, then plummeted by -52bps to 1.01% in 2023, then plummeted by -1473bps to 15.82% in 2024, then skyrocketed by 82bps to 2.81% in 2025.
  • Its Return on Equity was 2.81% in Q3 2025, compared to 52.01% in Q2 2025 and 8.3% in Q1 2025.